We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Therapy-induced secretion of spliceosomal components mediates pro-survival crosstalk between ovarian cancer cells.
- Authors
Shender, Victoria O.; Anufrieva, Ksenia S.; Shnaider, Polina V.; Arapidi, Georgij P.; Pavlyukov, Marat S.; Ivanova, Olga M.; Malyants, Irina K.; Stepanov, Grigory A.; Zhuravlev, Evgenii; Ziganshin, Rustam H.; Butenko, Ivan O.; Bukato, Olga N.; Klimina, Ksenia M.; Veselovsky, Vladimir A.; Grigorieva, Tatiana V.; Malanin, Sergey Y.; Aleshikova, Olga I.; Slonov, Andrey V.; Babaeva, Nataliya A.; Ashrafyan, Lev A.
- Abstract
Ovarian cancer often develops resistance to conventional therapies, hampering their effectiveness. Here, using ex vivo paired ovarian cancer ascites obtained before and after chemotherapy and in vitro therapy-induced secretomes, we show that molecules secreted by ovarian cancer cells upon therapy promote cisplatin resistance and enhance DNA damage repair in recipient cancer cells. Even a short-term incubation of chemonaive ovarian cancer cells with therapy-induced secretomes induces changes resembling those that are observed in chemoresistant patient-derived tumor cells after long-term therapy. Using integrative omics techniques, we find that both ex vivo and in vitro therapy-induced secretomes are enriched with spliceosomal components, which relocalize from the nucleus to the cytoplasm and subsequently into the extracellular vesicles upon treatment. We demonstrate that these molecules substantially contribute to the phenotypic effects of therapy-induced secretomes. Thus, SNU13 and SYNCRIP spliceosomal proteins promote therapy resistance, while the exogenous U12 and U6atac snRNAs stimulate tumor growth. These findings demonstrate the significance of spliceosomal network perturbation during therapy and further highlight that extracellular signaling might be a key factor contributing to the emergence of ovarian cancer therapy resistance. Ovarian cancers frequently develop resistance to therapy. Here, using transcriptomics, proteomics, and preclinical models to analyse paired ascitic fluids before and after chemotherapy in ovarian cancer patients, the authors discover that extracellular secretion and spliceosomal components contribute to therapy resistance, enhancing the DNA damage response in recipient cancer cells.
- Subjects
ASCITIC fluids; DNA repair; OVARIAN cancer; CANCER cells; EXTRACELLULAR vesicles; CANCER chemotherapy; SECRETION
- Publication
Nature Communications, 2024, Vol 15, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-024-49512-6